We examined cellular membrane fatty acid composition and insulin sensitivity in patients with mild essential hypertension and hyperlipidemia, and investigated whether bezafibrate, a lipid-lowering drug, could improve elevated blood pressure and insulin sensitivity in these subjects by ameliorating cellular membrane fatty 
Introduction
Metabolic and physiologic abnormalities associated with insulin resistance, such as hypertension, obesity, dyslipidemia, and glucose intolerance, may affect the vasculature, resulting in atherosclerotic disease (1) (2) (3) (4) . Impairment of the activities of insulin is thought to be centrally involved in these disorof free fatty acids in the portal vein has been related to metabolic disorders. The lipid composition of the cellular membrane is one of the most important determinants of cellular function. Abnormalities in the phospholipid and fatty acid composition of the cellular membrane have been found in hypertensive or hyperlipidemic subjects (9) . On the other hand, intracellular fatty acid kinetics are known to be a regulatory mechanism of insulin sensitivity (10) . These abnormalities may also be associated with cellular membrane lipid composition.
Bezafibrate is a widely used lipid-lowering fibric acid and a ligand of PPAR α. It has been reported that fibrates improve glucose tolerance and hypertension (11) (12) (13) (14) (15) (16) (17) . To elucidate the underlying mechanism of these phenomena, we examined the cellular membrane fatty acid composition and insulin sensitivity in patients with mild essential hypertension and hyperlipidemia, and investigated whether bezafibrate could improve elevated blood pressure and insulin sensitivity in these subjects by ameliorating cellular membrane fatty acid composition.
Methods

Study Protocol
We examined blood pressure and obtained fasting blood samples for biochemical screening as well as electrocardiograms in outpatients of Kobe University Hospital. Blood pressures of subjects in a sitting position were measured twice using a standard mercury sphygmomanometer. We recruited 27 men (50.5 1.6 years old, mean SEM) who had never been treated or had ceased taking their antihypertensive and -hyperlipidemic medication at least 3 months before the study. None of the patients had abnormal renal function or electrocardiographic evidence of left ventricular hypertrophy. Secondary causes of hypertension were ruled out by the usual screening tests, including history, physical examination, urinalysis, and blood chemistry. Twelve men with mild essential hypertension [systolic blood pressure (SBP) between 140 mmHg and 160 mmHg] and hypertriglyceridemia (plasma triglyceride concentration over 150 mg/dl) were designated the HL group. Fifteen men with mild essential hypertension and normotriglyceridemia (plasma triglyceride concentration below 150 mg/dl) were designated the NL group. All the subjects gave their informed consent to participate in the study. The study protocol was approved by the Human Ethics Committee of Kobe University School of Medicine.
Subjects in the HL group were treated with bezafibrate 400 mg/dl for 3 months. Subjects in the NL group were given placebo over the same period. Before and after administration, blood pressure examination and blood analysis were performed for all subjects. Blood pressure was measured three times by the same observer using a standard mercury sphygmomanometer after the subject had rested in a supine position for 30 min. Body mass index (BMI) was calculated by dividing body weight by the square of the height (kg/m 2 ).
Blood Sampling and Analysis
Blood samples were obtained at 9 AM after a 12-h fast. Patients had received neither drug nor placebo on the morning of examination. Plasma triglyceride, total cholesterol concentration, phospholipids, and free fatty acids were determined using enzymatic methods. High-density lipoprotein (HDL) cholesterol was assayed after precipitation of other lipoproteins with phosphotungstic acid and MgCl2. Lowdensity lipoprotein (LDL) cholesterol concentrations were calculated using Friedewald's formula (total cholesterol HDL cholesterol triglyceride/5) (18). Plasma apolipoprotein A1, A2, and B (apoA1, apoA2, and apoB) concentrations were examined by turbidimetric immunoassay methods. Plasma glucose concentrations were analyzed using the glucose-deoxygenase method and plasma insulin concentrations by radioimmunoassay. According to homeostasis model assessment (HOMA) (19) , insulin resistance (HOMA-R) and secretion (HOMA β-cell) were calculated as fasting plasma glucose (mg/dl) fasting insulin (µU/ml)/405 and 360 fasting insulin (µU/ml)/[fasting plasma glucose (mg/dl) 63], respectively. Glucose tolerance was examined by 75-g oral glucose tolerance test (OGTT) (20) at fasting, 30, 60, and 120 min. The difference in plasma insulin concentration divided by the difference in glucose concentration at 30 min (∆insulin/∆glucose) in 75-g OGTT was calculated for insulin secretion at an early stage. The cumulative glucose and insulin concentrations (total glucose, total insulin) were also evaluated. According to Cederholm and Wibell (21) , the insulin sensitivity index in 75-g OGTT was calculated for the evaluation of peripheral insulin sensitivity as [metabolic clearance rate/mean glucose concentration/log (mean insulin concentration)]; metabolic clearance rate was calculated as [75,000 mg/120 (fasting plasma glucose concentration plasma glucose at 120 min) 0.19 body weight/120].
Erythrocyte Membrane Fatty Acid Composition
Erythrocyte ghosts were obtained according to the method described by Hanahan and Ekholm (22) . Red cell membrane total lipids were extracted from washed erythrocyte ghosts according to the method of Bligh and Dyer (23) . After drying under a nitrogen stream, the samples were hydrolyzed and methylesterified with a 5% hydrogen chloride methanol solution (Wako Corp., Tokyo, Japan) for 1 h at 120°C. Fatty acid analysis was performed by gas chromatography (QP1000EX, Shimadzu, Kyoto, Japan). The column was a 2-m long 0.53 mm internal diameter (file thickness 1.5 µm) fused silica megabore column. Peaks were identified by comparison with known standards (Wako Corp.), and quantitative determinations were carried out by measuring the mass chromatogram peak areas. Fatty acid fractions, including total saturated fatty acids (SFA), total unsaturated fatty acids (USFA), total polyunsaturated fatty acids (PUFA), and total monounsaturated fatty acids (MUFA) were expressed as a percentage of the total fatty acids.
Statistical Analysis
Values were expressed as the mean SEM. Statistical significance of data was evaluated using either Student's t-test or Mann-Whitney U-test as appropriate. Correlations were calculated using the formula for Pearson's correlation coefficient. Statistical analysis was performed using Statview software (Abacus, Berkeley, USA). Two-tailed values of p 0.05 were considered statistically significant.
Results
Effect of Bezafibrate on Blood Pressure
We recruited and divided hypertensive patients into two groups according to the presence or absence of hypertriglyceridemia, and found no significant difference in age, BMI, pulse rate, or blood pressure between the HL and NL groups before treatment (Table 1) . Administration of bezafibrate for 3 months significantly reduced SBP and diastolic blood pressure (DBP) in the HL group (Table 1) .
Effect of Bezafibrate on Plasma Lipids
Before administration of placebo or bezafibrate, plasma triglyceride, apoB, phospholipid, and free fatty acid concentrations in the HL group were higher than those in the NL (Table 2 ). There was no significant difference in total cholesterol, LDL cholesterol, and HDL cholesterol concentrations between the two groups. Administration of bezafibrate decreased plasma triglyceride, apoB, and free fatty acid concentrations and increased plasma HDL cholesterol and apoA2 concentrations. There was no significant increase in plasma apoA1 concentration. Apart from triglyceride and apoA2, there was no significant difference in plasma lipids and apolipoprotein concentrations between the two groups at the end of the study period.
Effect of Bezafibrate on Glucose Metabolism
Before treatment, plasma glucose concentrations at fasting and each period in 75-g OGTT were similar in both groups. However, plasma insulin concentrations at fasting and 120 min, and total insulin, HOMA-R, and HOMA β-cell in the HL group were significantly higher than in the NL group. The insulin sensitivity index in the HL group was significantly lower than that in the NL group. After treatment, 75-g OGTT was performed only in the HL group (Table 3) . Plasma glucose (at fasting, 60 min, 120 min, and total glucose), plasma insulin (at fasting, 30 min, 120 min, and total insulin), and HOMA-R were significantly reduced. The insulin sensitivity index was improved significantly. HOMA β-cell and ∆insulin/∆glucose at 30 min were not changed significantly.
Effect of Bezafibrate on Erythrocyte Membrane Fatty Acid Composition
Before treatment, fatty acid fractions of PUFA, especially C20:5 and C22:6, were lower in the HL group than the NL group (Table 4) . After treatment, SFA was decreased and USFA was increased significantly in the HL group. Although the increase of PUFA was not significant, the percentages of C20:2, C22:2, and C24:2 were significantly increased.
Relationship between Plasma Triglyceride and Glucose Metabolism or Fatty Acid Composition
Plasma triglyceride concentrations were positively correlated with fasting insulin (r 0.52, p 0.01), insulin at 120 min (r 0.60, p 0.005), HOMA-R (r 0.50, p 0.01), and SFA (r 0.39, p 0.05), USFA (r 0.39, p 0.05), and PUFA (r 0.45, p 0.05) before administration of placebo or bezafibrate (Fig. 1) .
Discussion
In the present study we demonstrated that administration of bezafibrate for 3 months significantly decreased plasma triglyceride concentrations, reduced SBP and DBP, improved insulin sensitivity, and altered erythrocyte membrane fatty acid compositions in hyperlipidemic hypertensive patients. Before treatment, a decrease of USFA, particularly long-chain PUFA, and an increase of SFA in the erythrocyte membrane was observed. Bezafibrate administration induced a decrease in SFA and an increase in PUFA. Interestingly, plasma triglyceride concentrations were correlated not only with insulin sensitivity or concentration but also with erythrocyte membrane fatty acid composition. These results indicate that plasma lipid composition may play an important role in metabolic disorders.
Cell membrane fatty acids maintain a dynamic equilibrium with serum lipids (24) . Changes observed in the fatty acid composition of the erythrocyte membrane are thought to occur in the cell membranes of other tissue (25) . An increased unsaturation of the phospholipid acyl chain, particularly the n-3 fatty acids, is known to increase cell membrane fluidity (26, 27) . Borkman et al. (9) reported that the fatty acid composition of the phospholipids of skeletal muscle, one of the target tissues of insulin, was associated with insulin sensitivity and that the decrease in insulin sensitivity was correlated with the decrease in total PUFA, especially long-chain PUFA. These results are compatible with our present data. In the present study, we could not determine whether the alteration of fatty acid compositions was due to insulin resistance, but we could recognize that lowering plasma triglyceride concentration with bezafibrate improved both fatty acid compositions and insulin sensitivity in humans. Matsui et al. (28) demonstrated that bezafibrate in insulin-resistant rats improved insulin sensitivity and fatty acid composition of skeletal muscle triglycerides. Furuhashi et al. (17) also reported that fenofibrate in insulin-resistant rats improved insulin sensitivity by reducing intramusclar lipid content via further induction of fatty acid binding protein and stimulation of β-oxidation in muscles.
It has been reported that hyperinsulinemia is a determinant of membrane fluidity of erythrocytes in essential hypertension (29) . In the present study we demonstrated that administration of bezafibrate decreased fasting insulin concentration and improved the HOMA-R and insulin sensitivity index, but not either HOMA β-cell nor ∆insulin/∆glucose. One can deduce that bezafibrate may elevate fasting hepatic glucose uptake, reduce fasting hepatic glucose release, or improve peripheral insulin sensitivity, and that fasting pancreatic insulin secretion is not elevated. As a result, there was a decrease in the total insulin secreted after 75-g OGTT. Hyperinsulinemia causes blood pressure elevation through sodium retention by the kidneys, increased sympathetic nervous system activity, elevated vasoconstriction, and remodeling of the vasculature. Improvement of hyperinsulinemia may have decreased blood pressure in our study. The lowering of plasma triglyceride concentrations is related with a decrease of blood viscosity and cellular membrane fluidity.
Moreover, n-3 PUFA including fish oil can reduce serum triglyceride concentrations and blood pressure in stress-, salt-, and fructose-induced hypertension in borderline hypertensive rats (30, 31) and hypertensive humans (32) (33) (34) . Eicosapentaenoic acid can modulate cellular membrane lipid compositions, modulate intracellular Ca 2 signaling and intracellular cation transport associated with hypertension (34, 35) , stimulate nitric oxide release (36) , and improve insulin sensitivity (37) . Interventional studies have suggested that intracellular cationic contents can be affected by changes in membrane phospholipid composition through modification of transmembrane cationic transport systems (38) (39) (40) .
On the other hand, fibrates can modulate the synthetic balance of prostaglandins, thromboxanes, leukotriens, and lipoxins (41) . Of these, 20-hydroxyeicosatetraenoic acid, derived from arachidonic acid by the use of clofibrate, can alter the diuresis curve in the kidney. Thus these effects may cause the reduction of blood pressure in either an insulin sensitivity-dependent or -independent manner. In addition, troglitazone, an insulin-sensitizing drug, could improve blood pressure in diabetic subjects (42) . Taken together, these results suggest that the possible mechanisms underlying these phenomena improve metabolic disorders by regulation of insulin concentration, regulation of plasma and cell membrane lipid composition, activation of PPAR-related genes and proteins, and regulation of electrolyte balance in many organs and tissues involving vascular endothelial cells.
Some limitations of our study should be mentioned. First, our results did not include follow-up data of 75-g OGTT in normolipidemic subjects, examination of placebo effects on blood pressure, lipids, and insulin sensitivity in hyperlipidemic subjects, or analysis by the euglycemic hyperinsulinemic glucose clamp method. Furthermore, we may have achieved better results if we had performed a cross-over trial in the HL and NL group with bezafibrate and placebo. These analyses were difficult to pursue in the present series due to ethical and technical problems related to the use of outpatients. Second, we could not determine which was more important, hypertriglyceridemia or hyperinsulinemia, in blood pressure regulation in humans. This question is difficult to answer because the published reports have tended to use different animal species and models, different durations of intervention of drugs or diets, and different degrees of metabolic abnormalities. Fujioka et al. (31) demonstrated that an improvement of hyperinsulinemia led to a decrease in blood pressure in fructose-fed borderline hypertensive rats. Further experiments are needed to elucidate the details of blood pressure regulation in metabolic disorders.
In conclusion, the bezafibrate-induced improvement of hyperlipidemia may be attributed to reduction of blood pressure and amelioration of insulin sensitivity. Abnormalities in membrane lipid composition may play an important role in metabolic disorders.
